Clinical trial · Observational
Hepatobiliary Tumors Tissue Samples Acquisition
Acquisition of Blood and Tumor Tissue Samples From Patients With Hepatobiliary Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Hepatobiliary tumors have a poor prognosis and high individual heterogeneity, so it is of great significance to find important prognostic markers and then screen out specific subgroups of people; meanwhile, chronic hepatitis, cirrhosis, and healthy control participants also need to show the evolution of tumors and discover specific diagnostic markers as a control group. Moreover, targeted therapy and immunotherapy make cancer treatment enter a new field, but only part of patients achieve response rates and reach clinical benefit. However, these drugs are expensive and can cause treatment-related adverse events. Therefore, reliable biomarkers identification is needed to help predict the response to these treatment options in order to screen patients with better responsiveness and avoid wasting money. Multi-omics research can reveal the characteristics of hepatobiliary tumors more deeply and find meaningful therapeutic targets. Therefore, 450 patients at least 18 years of age with hepatobiliary tumors were included in this study.
Conditions
Conditions (8)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Benign Hepatobiliary Disease | — | UNRESOLVED | — |
| Biliary Tract Cancer | Malignant Biliary Tract Neoplasm | ALIAS | 0.90 |
| Cholangiocarcinoma | Cholangiocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Gallbladder Cancer | Malignant Gallbladder Neoplasm | CURATED_EXACT | 0.92 |
| Healthy, no Evidence of Disease | — | UNRESOLVED | — |
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
| Precancerous Condition | — | UNRESOLVED |
Interventions
Interventions (11)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gene expression analysis | Other | — | UNRESOLVED |
| Genomic analysis | Other | — | UNRESOLVED |
| Immunohistochemistry | Other | — | UNRESOLVED |
| Laboratory biomarker analysis | Other | — | UNRESOLVED |
| Liquid biopsy analysis | Other | — | UNRESOLVED |
| Mass spectrometry | Other | — | UNRESOLVED |
| Metabolomics profiling | Other | — | UNRESOLVED |
| Methylation and epigenetic analysis | Other | — | UNRESOLVED |
| Polymerase chain reaction |
Design
Arms and outcomes
Arms (2)
- label
- hepatobiliary tumor patients
- description
- benign or malignant hepatobiliary tumors patients
- interventionNames
- Other: Gene expression analysis
- Other: Genomic analysis
- Other: Protein expression analysis
- Other: Proteomic profiling
- Other: Polymerase chain reaction
- Other: Mass spectrometry
- Other: Immunohistochemistry
- Other: Metabolomics profiling
- Other: Methylation and epigenetic analysis
- Other: Liquid biopsy analysis
- Other: Laboratory biomarker analysis
- label
- Benign Hepatobiliary Disease
- description
- chronic hepatitis, cirrhosis, and healthy control
- interventionNames
- Other: Gene expression analysis
- Other: Genomic analysis
- Other: Protein expression analysis
- Other: Proteomic profiling
- Other: Polymerase chain reaction
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Be older than 18 years old; 2. ECOG 0-2 points; 3. May have received treatment; 4. Clinical consideration or diagnosis of benign and malignant hepatobiliary tumors; or chronic hepatitis, cirrhosis, or healthy control participants; 5. Patients may have received or are about to undergo surgery, chemotherapy, radiotherapy, targeted therapy, local therapy, immunotherapy, etc.; 6. Patients understand and are willing to sign written informed consent documents. Exclusion Criteria: 1. The doctor thinks it is not suitable to enter the group (mental disorder or poor compliance, etc.) 2. Pregnant women; 3. Active or uncontrollable infections (fungi, bacteria, etc.); 4. Estimated survival time \<12 weeks; 5. If the patient is receiving chronic anticoagulant therapy, the anticoagulant withdrawal should not be shorter than 3 days; 6. In the evaluation of the doctor, there is a risk of uncontrolled complications in the biopsy.
References
Publications (23)
- BACKGROUNDVillanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019 Apr 11;380(15):1450-1462. doi: 10.1056/NEJMra1713263. No abstract available. PMID 30970190
- BACKGROUNDBanales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RI, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJ, Alvaro D. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016 May;13(5):261-80. doi: 10.1038/nrgastro.2016.51. Epub 2016 Apr 20. PMID 27095655
- BACKGROUNDEuropean Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018 Jul;69(1):182-236. doi: 10.1016/j.jhep.2018.03.019. Epub 2018 Apr 5. No abstract available. PMID 29628281
- BACKGROUNDZhou J, Sun HC, Wang Z, Cong WM, Wang JH, Zeng MS, Yang JM, Bie P, Liu LX, Wen TF, Han GH, Wang MQ, Liu RB, Lu LG, Ren ZG, Chen MS, Zeng ZC, Liang P, Liang CH, Chen M, Yan FH, Wang WP, Ji Y, Cheng WW, Dai CL, Jia WD, Li YM, Li YX, Liang J, Liu TS, Lv GY, Mao YL, Ren WX, Shi HC, Wang WT, Wang XY, Xing BC, Xu JM, Yang JY, Yang YF, Ye SL, Yin ZY, Zhang BH, Zhang SJ, Zhou WP, Zhu JY, Liu R, Shi YH, Xiao YS, Dai Z, Teng GJ, Cai JQ, Wang WL, Dong JH, Li Q, Shen F, Qin SK, Fan J. Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). Liver Cancer. 2018 Sep;7(3):235-260. doi: 10.1159/000488035. Epub 2018 Jun 14. PMID 30319983
- BACKGROUNDLlovet JM, Montal R, Villanueva A. Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. J Hepatol. 2019 Jun;70(6):1262-1277. doi: 10.1016/j.jhep.2019.01.028. Epub 2019 Mar 31. PMID 30943423
- BACKGROUNDValle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D; ESMO Guidelines Committee. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016 Sep;27(suppl 5):v28-v37. doi: 10.1093/annonc/mdw324. No abstract available.